LYZZ Capital
Shanghai, Shanghailyzzcap.com
Overview
LYZZ Capital is a leading global healthcare-dedicated VC/PE firm that is actively investing out of USD and RMB funds totaling over USD$600 million . The LYZZ team is composed of highly experienced investment and operating professionals from leading pharmaceutical/biotech companies and Wall Street firms with strong scientific and medical professional backgrounds . They invest in talents, assets, and technologies globally, with an emphasis on unmet medical needs and large market potential in China .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Onchilles Pharma | Nov 2025 | Series A Extension | Co-investor |
| Wugen | Aug 2025 | Early Funding | Co-investor |
| Allotera Therapeutics | Aug 2025 | Series C | Co-investor |
| Mojia Bio | Jun 2022 | Series B | Co-investor |
| OncoMyx Therapeutics | Dec 2021 | Series B | - |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
